X0306 four 2017-12-06 zero 0001652130 Intellia Therapeutics, Inc. NTLA 0001377759 Bermingham Nessan C/O INTELLIA THERAPEUTICS, INC. 40 ERIE STREET; SUITE 130 CAMBRIDGE MA 02139 one one zero zero President & CEO Common Stock 2017-12-06 four S zero ninety-nine thousand and thirty-three twenty point two seven eight D six hundred and ninety-six thousand D Common Stock 2017-12-06 four S zero twelve thousand four hundred and sixty-seven twenty point eight three nine eight D six hundred and eighty-three thousand five hundred and thirty-three D Common Stock 2017-12-07 four S zero one hundred and three thousand five hundred and seventy-four twenty-one point zero five one four D five hundred and seventy-nine thousand nine hundred and fifty-nine D Common Stock 2017-12-07 four S zero twenty-seven thousand five hundred and sixty-six twenty-one point four five seven two D five hundred and fifty-two thousand three hundred and ninety-three D Common Stock 2017-12-08 four S zero ninety-four thousand one hundred and forty-three twenty point eight two one D four hundred and fifty-eight thousand two hundred and fifty D The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $19.70 to $20.69. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.70 to $21.12. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.33 to $21.32. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $21.33 to $21.65. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. The shares were sold pursuant to a Rule 10b5-1 trading plan. The price reflected is the average price per share for the transactions that are aggregated and reported on the line. Shares ranged in price from $20.51 to $21.48. The reporting person will provide to the Commission, the issuer and any stockholder, upon request, full information regarding the number of shares purchased or sold at each separate price. /s/Jose E. Rivera, Attorney-In-Fact 2017-12-08